Detalhe da pesquisa
1.
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Oncologist
; 28(10): 919-e972, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279797
2.
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Future Oncol
; 16(14): 899-909, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32270710
3.
A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.
J Transl Med
; 16(1): 196, 2018 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30012146
4.
Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Cancer
; 122(4): 588-597, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26566079
5.
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.
Cancer
; 119(7): 1357-64, 2013 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23280317
6.
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.
Invest New Drugs
; 31(1): 77-84, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22370972
7.
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
J Exp Clin Cancer Res
; 42(1): 76, 2023 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36991390
8.
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Clin Cancer Res
; 29(8): 1450-1459, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705597
9.
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Clin Cancer Res
; 29(2): 349-363, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099324
10.
Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.
Gynecol Oncol
; 120(1): 5-10, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20950846
11.
Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
Oncotarget
; 10(30): 2855-2868, 2019 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31080557
12.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
J Immunother Cancer
; 7(1): 197, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345267
13.
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Clin Cancer Res
; 29(2): 501, 2023 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36647676
14.
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
J Exp Clin Cancer Res
; 42(1): 102, 2023 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37101182
15.
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
J Clin Oncol
; 35(19): 2193-2202, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28471727
16.
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
Clin Cancer Res
; 23(6): 1397-1406, 2017 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663600
17.
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer.
Front Oncol
; 5: 123, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26082895
18.
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.
Mol Clin Oncol
; 1(3): 565-569, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24649212